Baili Tianheng (688506.SH): Rulongizumab for Injection Included in the National Medical Insurance Catalog

Zhitong Finance APP News, Baili Tianheng (688506.SH) announced that the Company's wholly-owned subsidiary Chengdu Baili Duote Biological Pharmaceutical Co., Ltd. independently developed the world's first-in-class, new-concept, and currently the world's first and only approved EGFRHER3 bispecific antibody-drug conjugate (ADC) drug for injection, "Lun Kang Yi Long Tuo Monoclonal Antibody" (iza-bren), was successfully included in the National Medical Insurance Catalog (2026 Edition) through national medical insurance negotiations in its first year on the market. The reimbursement scope of the drug is limited to adult patients with recurrent/metastatic nasopharyngeal carcinoma who have failed prior treatment with at least second-line systemic chemotherapy (and have used PD-1/PD-L1 inhibitors).